ResMed (RMD) investor relations material

Company overview

• Operates as a global leader in connected and digital health, focusing on sleep, breathing, and home health solutions, serving over 140 countries and employing more than 11,300 people.

• FY26 headline revenue reached approximately $5.7B, with 8% year-over-year constant currency growth and a non-GAAP operating margin of 35%.

• Strategic focus areas include operational and innovation excellence, active portfolio management, and disciplined capital allocation.

• Large, underpenetrated total addressable market in sleep apnea, COPD, insomnia, and restless legs syndrome, with significant growth runway.

• Mission centers on empowering 500M people by 2030 through life-changing health technologies and personalized care pathways.

Product portfolio

• Comprehensive device lineup led by AirSense 11, AirCurve 11, and AirMini, covering CPAP, APAP, bilevel, and portable therapy.

• Market-leading mask portfolio and diagnostic solutions, including AirTouch, AirFit, Virtuox, and NightOwl, supporting patient engagement before and during therapy.

• Residential Care Software platforms Brightree and MEDIFOX DAN digitize and connect post-acute and home care operations in the US and Germany.

• Robust digital ecosystem with over 28B nights of data, 37M+ patients on AirView, and 12.5M+ on myAir, leveraging AI for personalized therapy and engagement.

• Expansion into RLS therapy with Noctrix, a non-invasive, drug-free device, addressing a significant comorbid population.

Business and market updates

• Key partnerships, such as with OURA, expand access to sleep health education and care, with early KPIs showing high engagement and undiagnosed patient identification.

• Real-world data shows patients on GLP-1s are more likely to initiate and adhere to PAP therapy, with higher resupply rates over time.

• PAP therapy remains the primary treatment for OSA, with faster initiation rates compared to GLP-1s after diagnosis.

• Demographic shifts show increasing shares of women and younger patients among new OSA starts, influencing product design and education.

• Over 95,000 CME courses completed by 55,000+ clinicians, with 77% intending to change clinical practice regarding OSA.